Benserazide

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584159

CAS#: 322-35-0

Description: Benserazide is an inhibitor of dopa decarboxylase that does not enter the central nervous system. It is often given with levodopa in the treatment of parkinsons to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no anti-parkinsons actions when given alone.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-08-15. Prices are subject to change without notice.

Benserazide is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 584159
Name: Benserazide
CAS#: 322-35-0
Chemical Formula: C10H15N3O5
Exact Mass: 257.1012
Molecular Weight: 257.24
Elemental Analysis: C, 46.69; H, 5.88; N, 16.33; O, 31.10


Synonym: Benserazide; Serazide; Ro 44602; Ro-44602; Ro44602

IUPAC/Chemical Name: DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide

InChi Key: BNQDCRGUHNALGH-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)

SMILES Code: NC(CO)C(NNCC1=CC=C(O)C(O)=C1O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Wan Y, Wu N, Song L, Wang X, Liu Z, Yuan W, Gan J. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease. Front Aging Neurosci. 2017 Oct 18;9:331. doi: 10.3389/fnagi.2017.00331. eCollection 2017. PubMed PMID: 29093677; PubMed Central PMCID: PMC5651254.

2: Wollmer E, Klein S. Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices. J Pharm Pharm Sci. 2017;20(0):258-269. doi: 10.18433/J3K923. PubMed PMID: 28810948.

3: Pellegrini C, Antonioli L, Colucci R, Tirotta E, Gentile D, Ippolito C, Segnani C, Levandis G, Cerri S, Blandini F, Barocelli E, Ballabeni V, Bernardini N, Blandizzi C, Fornai M. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Neuropharmacology. 2017 Sep 1;123:22-33. doi: 10.1016/j.neuropharm.2017.05.016. Epub 2017 May 17. PubMed PMID: 28526609.

4: Li W, Zheng M, Wu S, Gao S, Yang M, Li Z, Min Q, Sun W, Chen L, Xiang G, Li H. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res. 2017 Apr 20;36(1):58. doi: 10.1186/s13046-017-0530-4. PubMed PMID: 28427443; PubMed Central PMCID: PMC5399312.

5: Druzhyna N, Szczesny B, Olah G, Módis K, Asimakopoulou A, Pavlidou A, Szoleczky P, Gerö D, Yanagi K, Törö G, López-García I, Myrianthopoulos V, Mikros E, Zatarain JR, Chao C, Papapetropoulos A, Hellmich MR, Szabo C. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer. Pharmacol Res. 2016 Nov;113(Pt A):18-37. doi: 10.1016/j.phrs.2016.08.016. Epub 2016 Aug 10. PubMed PMID: 27521834; PubMed Central PMCID: PMC5107130.

6: Guo G, Xu S, Cao LD, Wu QY. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2409-12. PubMed PMID: 27338068.

7: Alirezaei M. Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats. Iran J Basic Med Sci. 2015 Oct;18(10):950-7. PubMed PMID: 26730328; PubMed Central PMCID: PMC4686578.